Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(40%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)

Detailed Status

Withdrawn1
Completed1
Active, not recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

withdrawn120%
completed120%
active_not_recruiting120%
terminated120%
recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317
active_not_recruitingphase_1

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287
terminatedphase_2

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

NCT05799079
completedphase_1

Thorough QT Assessment of Cedazuridine in Healthy Subjects

NCT04953923
withdrawnphase_2

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

NCT04985656

Clinical Trials (5)

Showing 5 of 5 trials
NCT04256317Phase 2

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Recruiting
NCT03875287Phase 1

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Active Not Recruiting
NCT05799079Phase 2

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Terminated
NCT04953923Phase 1

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Completed
NCT04985656Phase 2

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5